Dr Tony Holohan, Chief Medical Officer, has published his report on the clinical and technical issues associated with the use of Uro-Gynaecological Mesh (also referred to as Transvaginal Mesh Implants (TVMIs)).
Dr Holohan prepared the report in response to a number of concerns raised about the frequency and severity of complications associated with the use of TVMIs in some women. TVMIs have been widely used in the surgical treatment of stress urinary incontinence (SUI) and pelvic organ prolapse (POP) in women. It is widely accepted that for many women suffering the distressing symptoms of SUI in particular, surgical procedures using synthetic mesh devices have provided a more effective and less invasive form of treatment than traditional surgical procedures. However, mesh devices are associated with significant and severe complications in a minority of women, which are of concern given the difficulties of mesh implant removal.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
